Dr. Sio on Optimal Radiation Therapy Dose in Locally Advanced NSCLC

Video

Terence T. Sio, MD, MS, discusses the standard-of-care dose of radiation therapy in locally advanced, non–small cell lung cancer.

Terence T. Sio, MD, MS, radiation oncologist and assistant professor of radiation oncology at Mayo Clinic, discusses the standard-of-care dose of radiation therapy in locally advanced, non—small cell lung cancer (NSCLC).

In the modern era, the standard-of-care for patients with locally advanced NSCLC who require concurrent chemotherapy and radiation therapy is 60 gray (Gy), says Sio. This dosage is delivered Monday through Friday, at 2 Gy/day per fraction, for the duration of 6 weeks.

The NRG Oncology RTOG 0617 trial set out to determine whether a higher dose of radiation, 74 Gy, with concurrent chemotherapy would be more beneficial than the standard dose of 60 Gy, in patients with unresectable stage III NSCLC, says Sio. Investigators noted more adverse events in those who received the higher dose, with no improvement in overall survival. As such, 60 Gy continues to be the standard-of-care radiation dose in this patient population, concludes Sio.

Related Videos
Deepak L. Bhatt, MD, MPH, MBA, on Incorporating AI into Genetic Research for Cardiovascular Disease
Jeffrey Chamberlain, PhD, on Helping Progress Cell and Gene Therapy Development
Jonathan W. Weinsaft, MD, on Integrating Genetic Research into Cardiovascular Medicine
Jacques Galipeau, MD, on Highlights from ISCT 2024’s Presidential Plenary
Vanee Pho, PhD, the senior director of product management, cell and gene therapy, at Mission Bio
Michael Wang, MD, a professor in the Department of Lymphoma/Myeloma at MD Anderson Cancer Center
Robert J. Hopkin, MD, on Looking Deeper into Fabry Disease Biology
Steven W. Pipe, MD, on Confirming Efficacy, Safety of Hemgenix Gene Therapy in Hemophilia B Populations
Rawan Faramand, MD, an assistant professor at Moffit Cancer Center
Marcus Conant, MD, on More Research Needed With HIV Therapies
© 2024 MJH Life Sciences

All rights reserved.